CPI-818

Phase 1Small molecule

CCorvus Pharmaceuticals, Inc.

CPI-818 is one of 27 small molecule programs targeting Lymphoma. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

LymphomaActive, not recruiting

LymphomaPhase 1

Active, not recruiting

Competition

Competitive Landscape

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

Velban

EEastern Cooperative Oncology Group

Preclinical

15 2

Zofran

Novartis

Preclinical

2 3

Wellcovorin

GGlaxo Dba Glaxosmithkline

Preclinical

4 4

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 5

Nuvigil

NNuvo Research GmbH

Preclinical

1 6

Elitek

AAzienda U.S.L. 1 di Massa e Carrara

PEG-Intron

1 8

Systemic Therapy

Bristol-Myers Squibb

Preclinical

1 9

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Preclinical

—10

CAR-T

HHebei Senlang Biotechnology Inc., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Lymphoma1 trial

A Dose Escalation Study Evaluating CPI-818 in Relapsed/Refractory T-Cell Lymphoma

Active, not recruiting·CCorvus Pharmaceuticals, Inc.·Phase 1·NCT03952078·151 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for CPI-818. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CPI-818 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CPI-818. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Corvus Pharmaceuticals, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: CCorvus Pharmaceuticals, Inc.

CPI-818

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Lymphoma1 trial

References

Drug Info

Quick Facts

Related News